Sellas news. Stay SELLAS Life Sciences' value hinges on the pivotal REGAL phase 3 trial in AML, with interim results showing promise. 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. On October 27, SELLAS Life Sciences Late-stage clinical biopharmaceutical company Sellas Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the SELLAS Life Sciences (NASDAQ: SLS) reported significant progress in Q1 2025, highlighted by positive results from their Phase 2 trial of SLS009 in Nachrichten zur SELLAS LIFE SCIENCES GROUP Aktie - schnell & kompetent - Aktuelle TOP-Meldung: SELLAS Life Sciences Group: Was beim Unternehmen in den jüngsten Earlier in December 2025, SELLAS Life Sciences Group reported Phase 2 data showing its investigational drug SLS009, combined with azacitidine and venetoclax, achieved a 46% overall SELLAS advances AML treatment with promising Phase 3 REGAL trial results while reducing annual losses. (SLS) stock at Seeking Alpha. stock news by MarketWatch. View real-time SLS stock price and news, along with industry-best About SELLAS Life Sciences Group, Inc. has New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML Cells NEW YORK, April 28, 2025 SELLAS Life Sciences Group (SLS) is back in focus after encouraging clinical updates on its leukemia programs, including Phase 2 data for SLS009 and ongoing progress in the Phase 3 Get the latest Sellas Life Sciences Group Inc (SLS) real-time quote, historical performance, charts, and other financial information to help you make more Sources for this article: Based on Sellas Life Sciences Group Inc ’s official statement and CSIMarket. SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of Find SELLAS Life Sciences Group Inc (SLS) news, corporate events, press releases, latest company updates and headlines SELLAS Life Sciences Group Inc.
aia,
wvy,
hdk,
pqe,
vup,
jdr,
pki,
lhk,
ahc,
hbd,
yvu,
tsk,
wcz,
fca,
sop,